Posted by Michael Wonder on 01 Dec 2024
Attruby (acoramidis), a near complete TTR stabiliser (≥90%), approved by FDA to reduce cardiovascular death and cardiovascular related hospitalisation in ATTR-CM patients
22 November 2024 - Attruby is the first and only approved product with a label specifying near complete stabilisation of TTR.
BridgeBio Pharma today announced that the US FDA approved Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of transthyretin for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalisation.
